123 related articles for article (PubMed ID: 28671087)
21. Pharmacogenomic-pharmacokinetic study of selective estrogen-receptor modulators with intra-patient dose escalation in breast cancer.
Ishiguro H; Ohno S; Yamamoto Y; Takao S; Sato N; Fujisawa T; Kadoya T; Kuroi K; Bando H; Teramura Y; Iwata H; Tanaka S; Toi M
Breast Cancer; 2019 Sep; 26(5):535-543. PubMed ID: 30734152
[TBL] [Abstract][Full Text] [Related]
22. No association found between CYP2D6 genotype and early breast cancer events in tamoxifen-treated patients.
Markkula A; Hjertberg M; Rose C; Ingvar C; Jernström H
Acta Oncol; 2014 Feb; 53(2):195-200. PubMed ID: 24125101
[TBL] [Abstract][Full Text] [Related]
23. Potent CYP2D6 Inhibiting drugs do not increase relapse rate in early breast cancer patients treated with adjuvant tamoxifen.
Siegelmann-Danieli N; Kurnik D; Lomnicky Y; Vesterman-Landes J; Katzir I; Bialik M; Loebstein R
Breast Cancer Res Treat; 2011 Jan; 125(2):505-10. PubMed ID: 20593233
[TBL] [Abstract][Full Text] [Related]
24. Significant Effect of Polymorphisms in
Zembutsu H; Nakamura S; Akashi-Tanaka S; Kuwayama T; Watanabe C; Takamaru T; Takei H; Ishikawa T; Miyahara K; Matsumoto H; Hasegawa Y; Kutomi G; Shima H; Satomi F; Okazaki M; Zaha H; Onomura M; Matsukata A; Sagara Y; Baba S; Yamada A; Shimada K; Shimizu D; Tsugawa K; Shimo A; Tan EY; Hartman M; Chan CW; Lee SC; Nakamura Y
Clin Cancer Res; 2017 Apr; 23(8):2019-2026. PubMed ID: 27797974
[No Abstract] [Full Text] [Related]
25. Genotype of metabolic enzymes and the benefit of tamoxifen in postmenopausal breast cancer patients.
Wegman P; Vainikka L; Stål O; Nordenskjöld B; Skoog L; Rutqvist LE; Wingren S
Breast Cancer Res; 2005; 7(3):R284-90. PubMed ID: 15987423
[TBL] [Abstract][Full Text] [Related]
26. Impact of CYP2D6 polymorphisms on tamoxifen responses of women with breast cancer: a microarray-based study in Thailand.
Sukasem C; Sirachainan E; Chamnanphon M; Pechatanan K; Sirisinha T; Ativitavas T; Panvichian R; Ratanatharathorn V; Trachu N; Chantratita W
Asian Pac J Cancer Prev; 2012; 13(9):4549-53. PubMed ID: 23167378
[TBL] [Abstract][Full Text] [Related]
27. The CYP2D6*4 polymorphism affects breast cancer survival in tamoxifen users.
Bijl MJ; van Schaik RH; Lammers LA; Hofman A; Vulto AG; van Gelder T; Stricker BH; Visser LE
Breast Cancer Res Treat; 2009 Nov; 118(1):125-30. PubMed ID: 19189212
[TBL] [Abstract][Full Text] [Related]
28. [Clinicopathological features of endometrial carcinoma in tamoxifen- and toremifene-treated breast cancer patients].
Otsuka I; Takahashi S; O'uchi K; Akimoto N; Hanari K; Ogaki Y; Enatsu YH; Takigawa A; Takaya H; Tanaka A; Kaseki H; Yamada T
Gan To Kagaku Ryoho; 2010 Feb; 37(2):279-83. PubMed ID: 20154485
[TBL] [Abstract][Full Text] [Related]
29. CYP2D6 and adjuvant tamoxifen: possible differences of outcome in pre- and post-menopausal patients.
Margolin S; Lindh JD; Thorén L; Xie H; Koukel L; Dahl ML; Eliasson E
Pharmacogenomics; 2013 Apr; 14(6):613-22. PubMed ID: 23570465
[TBL] [Abstract][Full Text] [Related]
30. No association between CYP2D6*10 genotype and survival of node-negative Japanese breast cancer patients receiving adjuvant tamoxifen treatment.
Toyama T; Yamashita H; Sugiura H; Kondo N; Iwase H; Fujii Y
Jpn J Clin Oncol; 2009 Oct; 39(10):651-6. PubMed ID: 19596663
[TBL] [Abstract][Full Text] [Related]
31. No increase in breast cancer recurrence with concurrent use of tamoxifen and some CYP2D6-inhibiting medications.
Ahern TP; Pedersen L; Cronin-Fenton DP; Sørensen HT; Lash TL
Cancer Epidemiol Biomarkers Prev; 2009 Sep; 18(9):2562-4. PubMed ID: 19690182
[TBL] [Abstract][Full Text] [Related]
32. Association between genetic polymorphisms of CYP2D6 and outcomes in breast cancer patients with tamoxifen treatment.
Park HS; Choi JY; Lee MJ; Park S; Yeo CW; Lee SS; Shin JG; Park BW
J Korean Med Sci; 2011 Aug; 26(8):1007-13. PubMed ID: 21860550
[TBL] [Abstract][Full Text] [Related]
33. The Role of CYP2D6 Polymorphisms in Determining Response to Tamoxifen in Metastatic Breast Cancer Patients: Review and Egyptian Experience.
Malash I; Mansour O; Shaarawy S; Abdellateif MS; Omar A; Gaafer R; Zekri AN; Ahmed OS; Bahnassy A
Asian Pac J Cancer Prev; 2020 Dec; 21(12):3619-3625. PubMed ID: 33369460
[TBL] [Abstract][Full Text] [Related]
34. Association of genetic variation in tamoxifen-metabolizing enzymes with overall survival and recurrence of disease in breast cancer patients.
Nowell SA; Ahn J; Rae JM; Scheys JO; Trovato A; Sweeney C; MacLeod SL; Kadlubar FF; Ambrosone CB
Breast Cancer Res Treat; 2005 Jun; 91(3):249-58. PubMed ID: 15952058
[TBL] [Abstract][Full Text] [Related]
35. Re: CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1-98 trial and Re: CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients.
Pharoah PD; Abraham J; Caldas C
J Natl Cancer Inst; 2012 Aug; 104(16):1263-4; author reply 1266-8. PubMed ID: 22851268
[No Abstract] [Full Text] [Related]
36. Tamoxifen use in postmenopausal breast cancer: CYP2D6 matters.
Brauch H; Schroth W; Goetz MP; Mürdter TE; Winter S; Ingle JN; Schwab M; Eichelbaum M
J Clin Oncol; 2013 Jan; 31(2):176-80. PubMed ID: 23091108
[No Abstract] [Full Text] [Related]
37. Detection of Cytochrome P450 Polymorphisms in Breast Cancer Patients May Impact on Tamoxifen Therapy.
Thota K; Prasad K; Basaveswara Rao MV
Asian Pac J Cancer Prev; 2018 Feb; 19(2):343-350. PubMed ID: 29479969
[TBL] [Abstract][Full Text] [Related]
38. Toremifene-induced fatty liver and NASH in breast cancer patients with breast-conservation treatment.
Hamada N; Ogawa Y; Saibara T; Murata Y; Kariya S; Nishioka A; Terashima M; Inomata T; Yoshida S
Int J Oncol; 2000 Dec; 17(6):1119-23. PubMed ID: 11078796
[TBL] [Abstract][Full Text] [Related]
39. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy.
Goetz MP; Sangkuhl K; Guchelaar HJ; Schwab M; Province M; Whirl-Carrillo M; Symmans WF; McLeod HL; Ratain MJ; Zembutsu H; Gaedigk A; van Schaik RH; Ingle JN; Caudle KE; Klein TE
Clin Pharmacol Ther; 2018 May; 103(5):770-777. PubMed ID: 29385237
[TBL] [Abstract][Full Text] [Related]
40. A pooled analysis of CYP2D6 genotype in breast cancer prevention trials of low-dose tamoxifen.
Johansson H; Gandini S; Serrano D; Gjerde J; Lattanzi M; Macis D; Guerrieri-Gonzaga A; Aristarco V; Mellgren G; Lien E; DeCensi A; Bonanni B
Breast Cancer Res Treat; 2016 Aug; 159(1):97-108. PubMed ID: 27484880
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
